Summary: Scientists have engineered dozens of adeno-associated virus (AAV) systems that ferry genes to specific neuron and glial subtypes in the brain and spinal cord with unprecedented accuracy. Powered by AI-selected DNA “light switches,” the vectors can switch on therapeutic or research genes only in targeted cells, eliminating the need for transgenic animals and enabling fine-grained circuit mapping, activation, or silencing.
Validated across multiple species and human surgical tissue, the toolkit reaches elusive cells implicated in disorders like ALS, epilepsy, and Parkinson’s disease. By focusing treatment on malfunctioning cells alone, these tools lay a foundation for next-generation brain gene therapies that address root causes rather than symptoms.
Key Facts:
- Cell-Specific Vectors: Dozens of AAVs precisely…